Oliver Engert Acquires 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Monday, March 9th. The stock was purchased at an average price of $23.39 per share, with a total value of $23,390.00. Following the purchase, the insider owned 46,640 shares in the company, valued at approximately $1,090,909.60. This represents a 2.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Oliver Engert also recently made the following trade(s):

• On Friday, March 6th, Oliver Engert purchased 750 shares of Enovis stock. The shares were purchased at an average cost of $24.41 per share, for a total transaction of $18,307.50.
• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The shares were purchased at an average price of $25.10 per share, for a total transaction of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average cost of $24.77 per share, with a total value of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00.

Enovis Stock Performance

Shares of Enovis stock traded down $0.79 during mid-day trading on Tuesday, hitting $23.87. 975,171 shares of the stock were exchanged, compared to its average volume of 1,154,731. Enovis Corporation has a 12 month low of $21.00 and a 12 month high of $40.69. The company has a 50-day simple moving average of $23.97 and a 200 day simple moving average of $27.93. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The company has a market capitalization of $1.37 billion, a P/E ratio of -1.15 and a beta of 1.46.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of a number of recent analyst reports. Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. UBS Group restated a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. BTIG Research raised their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Finally, Needham & Company LLC increased their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Institutional Investors Weigh In On Enovis

Large investors have recently added to or reduced their stakes in the company. McIlrath & Eck LLC raised its stake in Enovis by 6.9% in the 3rd quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock valued at $167,000 after acquiring an additional 357 shares during the period. Farther Finance Advisors LLC boosted its position in Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Enovis by 6.1% in the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after purchasing an additional 495 shares in the last quarter. Amalgamated Bank increased its stake in shares of Enovis by 3.6% in the third quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after purchasing an additional 585 shares in the last quarter. Finally, Heritage Family Offices LLP raised its position in shares of Enovis by 8.9% in the third quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock valued at $231,000 after purchasing an additional 620 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.